Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

<p>SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) &#8212; Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/nkarta-presents-nkx101-clinical-data-at-the-2023-american-society-of-hematology-annual-meeting-exposition/">Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting &amp; Exposition</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>